Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
China Will Do What Is Needed to Boost Growth: Street
22:27 - Bill Street of State Street Global Advisors talks with Anna Edwards about the boost to Chinese manufacturing from stimulus measures and the seven-year high hit by the Shanghai Composite. He speaks on “On The Move.” (Source: Bloomberg)
  • Challenger Muhammadu Buhari Wins Nigeria's Presidency
  • Parity for Euro by End of the Year: BNP Paribas
  • ECB to Review Lifeline to Greek Banks